EUCTR2007-004018-15-ES进行中（未招募）1 期
A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery. Estudio aleatorizado, multicéntrico, doble ciego, de secuencias de grupos para evaluar la eficacia, la inmunogenia y la seguridad de una dosis única de la vacuna de Merck contra Staphylococcus aureus 0657nI (V710) en pacientes adultos citados para una intervención de cirugía cardiotorácica - V710 Cardiothoracic Surgery Efficacy, Immunogenicity, and Safety Study
Merck Sharp & Dohme de España, S.A.0 个研究点目标入组 5,700 人开始时间: 2007年12月5日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 5,700
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Patient is 18 years of age or greater.
- •2.Patient is scheduled to undergo cardiothoracic surgery involving a full median sternotomy (not including cardiac transplantation surgery) within 14 to 60 days postvaccination.
- •3.Female patients of reproductive potential are required to have a negative urine or serum pregnancy test immediately prior to study vaccination. Female patients of reproductive potential must have been using an acceptable form of birth control for two weeks prior to enrollment, and agree to use an acceptable method of birth control for one month postvaccination. Acceptable methods of birth control include use of hormonal contraceptives, intrauterine device (IUD), diaphragm with spermicide, contraceptive sponge, tubal ligation, condoms, or abstinence.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patient developed an invasive S. aureus infection (e.g., bacteremia, endocarditis, pneumonia, mediastinitis, osteomyelitis, etc.) in the three months prior to study entry.
- •2.Patient’s underlying condition is sufficiently unstable so that there is a realistic (>50%) possibility that cardiothoracic surgery will be necessary within the 10 days following study entry/vaccination.
- •3.Patient is planning to undergo cardiac transplantation surgery or sternal debridement to remedy an infection resulting from a prior cardiothoracic surgery.
- •4.Patient has received any other investigational S. aureus vaccine or any investigational S. aureus antibodies within the 12 months prior to study entry.
- •5.Patient has a temperature of =100.4ºF (=38.0ºC), oral equivalent, within 48 hours prior to study vaccination.
- •6.Patient was administered any immunoglobulin within 90 days prior to study vaccination or is scheduled to receive such products at any time through postoperative Day 90.
- •7.Patient has a known or suspected impairment of immunologic function including, but not limited to, the following conditions: autoimmune disease, moderate/severe hepatic insufficiency or cirrhosis, renal failure or insufficiency (on hemodialysis or peritoneal dialysis), immunoglobulin deficiency, or other congenital or acquired immunodeficiency, including HIV/AIDS.
- •8.Patient is currently pregnant or breastfeeding, or planning to conceive at any time throughout the duration of the study (through postoperative Day 90).
- •9.Patient has a medical condition in which the expected survival is less than 90 days.
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery.EUCTR2007-004018-15-FRaboratoires Merck Sharp and Dohme-Chibret5,700
进行中（未招募）
不适用
A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery. - V710 Cardiothoracic Surgery Efficacy, Immunogenicity, and Safety StudyStaphylococcus aureus bacteremiaStaphylococcus aureus mediastinitisMedDRA version: 9.1Level: LLTClassification code 10058887Term: Staphylococcus aureus bacteremiaMedDRA version: 9.1Level: LLTClassification code 10066413Term: Staphylococcus aureus mediastinitisEUCTR2007-004018-15-IEMerck Sharp & Dohme Ireland (Human Health) Limited8,044
进行中（未招募）
1 期
A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery. - V710 Cardiothoracic Surgery Efficacy, Immunogenicity, and Safety StudyEUCTR2007-004018-15-BEMerck Sharp & Dohme BV5,700
进行中（未招募）
1 期
A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery. - ND2.Patient is scheduled to undergo cardiothoracic surgery involving a full median sternotomy (not including cardiac transplantation surgery) within 14 to 60 days postvaccination.MedDRA version: 9.1 Level: LLT Classification code 10058080 Term: Staphylococcal infectionEUCTR2007-004018-15-ITMERCK SHARP DOHME3,600
进行中（未招募）
不适用
A Randomized, Multicenter, Double-Blind, Group-Sequential Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Single Dose of Merck 0657nI Staphylococcus aureus Vaccine (V710) in Adult Patients Scheduled for Cardiothoracic Surgery. - V710 Cardiothoracic Surgery Efficacy, Immunogenicity, and Safety StudyStaphylococcus aureus bacteremiaStaphylococcus aureus mediastinitisMedDRA version: 13.1Level: LLTClassification code 10058887Term: Staphylococcus aureus bacteremiaSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 13.1Level: LLTClassification code 10066413Term: Staphylococcus aureus mediastinitisSystem Organ Class: 10021881 - Infections and infestationsEUCTR2007-004018-15-GBMerck Sharp & Dohme Corp.5,700